Leniolisib phosphate

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-17635A 1354691-97-6 C ₂₁ H ₂₈ F ₃ N ₆ O ₆ P 548.45 PI3K PI3K/Akt/mTOR -20°C, sealed storage, away from moisture	F F O N N N H HO-P-OH O H
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	1.8233 mL	9.1166 mL	18.2332 mL		
		5 mM	0.3647 mL	1.8233 mL	3.6466 mL		
		10 mM	0.1823 mL	0.9117 mL	1.8233 mL		

BIOLOGICAL ACTIVITY									
Description	Leniolisib (CDZ173) phosphate is a potent and selective ΡΙ3Κδ inhibitor. Leniolisib phosphate has the potential for immunodeficiency disorders treatment.								
IC ₅₀ & Target	ΡΙ3Κδ 11 nM (IC ₅₀) DNA-PK 880 nM (IC ₅₀)	ΡΙ3Κα 280 nM (IC ₅₀)	ΡΙ3Κβ 480 nM (IC ₅₀)	ΡΙ3Κγ 2.57 nM (IC ₅₀)					
In Vitro	Expression of APDS mutant p110δ in cell lines and patient-derived lymphocytes lead to increased pathway activity, measured as phosphorylation of AKT or S6, which is suppressed by Leniolisib phosphate in a concentration dependent way ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								

REFERENCES



[1]. Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406

[2]. Hoegenauer K, et al. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Med Chem Lett. 2017 Aug 25;8(9):975-980.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA